Navigation Links
Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
Date:2/5/2013

HAYWARD, Calif., Feb. 5, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that Senior Vice President of Product Development Georgina Kilfoil has notified the company she will leave the company effective February 15, 2013 to pursue other opportunities.

"The Board and management of Anthera would like to thank Georgina for her years of dedicated service. Georgina's exemplary leadership and experience was instrumental in the advancement of Anthera's development programs. Her tireless efforts brought us to the starting line of our BRIGHT-SC phase 2 study for IgA Nephropathy and CHABLIS-SC phase 3 study for systemic lupus erythematosus, which we are excited to get underway this year," said Paul F. Truex , Anthera's President and Chief Executive Officer. "We wish Georgina all the best as she seeks to repeat her success in future endeavors."

Dr. Colin Hislop , Anthera's Senior Vice President and Chief Medical Officer, will continue to oversee all product development related activities for blisibimod.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to it
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
2. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
3. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
4. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
5. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
6. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
7. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
8. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
11. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Adeptus Health Inc. (NYSE: ADPT ) (the ... the previously announced offering of 2,100,000 shares of its ... to be sold by the Company, and 750,329 shares ... Partners (the "Selling Stockholder"), at a price to the ... and the Selling Stockholder have granted the underwriters an ...
(Date:5/5/2015)... BOSTON , May 5, 2015   InspireMD, Inc. ... in embolic protection systems, announced today that it will release ... 31, 2015 on Monday, May 11 th before the ... to review its financial results and business outlook. ... ) or (412) 542-4135 (International) and request the InspireMD call. ...
(Date:5/5/2015)... Calif. , May 5, 2015 ... biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic ... clinical trial evaluating tenapanor in Stage 3 chronic ... and albuminuria did not meet the primary endpoint ... patients compared to patients receiving placebo. ...
Breaking Medicine Technology:Adeptus Health Inc. Announces Pricing of Common Stock Offering 2Adeptus Health Inc. Announces Pricing of Common Stock Offering 3Adeptus Health Inc. Announces Pricing of Common Stock Offering 4InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6
(Date:5/5/2015)... (PRWEB) May 05, 2015 With the FCPX ... can quickly and easily add washed color grades to footage. ... formula for modifying an image. The LUT changes every pixel's ... pack comes with 90 washed CUBE LUT files. , This ... Monochromatic can give any footage a washed look. , ...
(Date:5/5/2015)... 2015 Private equity consultant and international ... announced that its dental stem cell biobank project, ... again--in April, 2015 –and posted yet another exciting record. ... volume and represents a significant 54% increase over last ... biobank is conducted via the Store-A-Tooth brand. The company ...
(Date:5/5/2015)... Beverly Hills Cosmetic Dentist, Arthur Glosman released a luxury ... sold at the offices of Arthur Glosman DDS, 450 N ... an online store . “I wanted to be one ... care and beauty with a luxurious collection of products designed ... , Dr. Glosman’s Advanced Dental Health + Beauty™ products ...
(Date:5/5/2015)... NCPDP announced today that AmerisourceBergen ... a three-year commitment of strategic support for NCPDP, and ... “AmerisourceBergen has supported our multi-stakeholder forum over 3 decades,” ... is a wonderful continuation and expansion of its commitment ... back to our very first Board of Trustees in ...
(Date:5/5/2015)... AxoGen, Inc. (NASDAQ: AXGN), ... billion peripheral nerve repair market, reported record revenue of ... 2015 compared to $3.14 million in the year-ago first ... proprietary portfolio of nerve repair products - Avance® ... – and our solid sales execution delivered another record ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:Beverly Hills Dentist Arthur Glosman Launches New Dental Health And Beauty Product Line 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4
... to Nutrition experts, some new ways of getting the ... that omega-6 fatty acids are associated with chronic diseases, ... regular daily diet naturally// includes some of each. ... your omega-3s from fish like sardines, salmon and tuna. ...
... spend more for health care and medications than smokers, ... health hazards. While tobacco is still the nation's principal ... obesity was running a close second. ,For ... Corp. economist Roland Sturm used data from two national ...
... human diet mean people today are more at risk of ... the University of Newcastle believe that changes to the way ... anti-cancer agents. ,The researchers are working on a ... stomach cancer. They are carrying out two trials on people ...
... in hospital who smoke and have a history of ... surveyed almost 400 patients// to find if there was ... classified them into four groups:current tobacco use only, history ... ,The patients with both current tobacco use and past ...
... According to researchers reducing weight and increasing exercise cut ... have elevated blood sugar are known to be at ... serious even life-threatening complications, it would be very useful ... individuals avoid the disease. ,Researchers for the ...
... longtime sufferers. New research shows that a combination of ... the severity and frequency of chronic tension headches, which ... people with mild to moderate head pain that occurs ... six months. Although antidepressants require a prescription, they may ...
Cached Medicine News:
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Symphony family of Pacemakers, Ela presents the ... lighter than a passport, will take your ... technologies, and delivering powerful monitoring. ELA ... dual-chamber and atrial tracking modes in patients ...
Medicine Products: